Inogen Inc. (INGN) Trading Down 2.3%
Inogen Inc. (NASDAQ:INGN) was down 2.3% during trading on Friday . The stock traded as low as $50.15 and last traded at $50.16, with a volume of 115,958 shares traded. The stock had previously closed at $51.35.
Several equities research analysts recently commented on INGN shares. Piper Jaffray Cos. started coverage on Inogen in a report on Thursday, March 24th. They issued a “neutral” rating and a $46.00 price objective for the company. Needham & Company LLC reiterated a “strong-buy” rating and issued a $58.00 price objective (up from $47.00) on shares of Inogen in a report on Tuesday, May 10th. Zacks Investment Research downgraded Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, May 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $52.00 price objective (up from $46.00) on shares of Inogen in a report on Tuesday, May 10th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $60.00 price objective on shares of Inogen in a report on Wednesday, June 8th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $52.83.
The stock’s 50 day moving average price is $49.09 and its 200-day moving average price is $42.38. The stock has a market capitalization of $1.01 billion and a price-to-earnings ratio of 86.04.
Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Monday, May 9th. The medical technology company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by $0.01. The company earned $43 million during the quarter, compared to analysts’ expectations of $41.75 million. Inogen’s revenue was up 27.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 EPS. Analysts anticipate that Inogen Inc. will post $0.60 earnings per share for the current year.
In related news, CEO Raymond Huggenberger sold 20,747 shares of the company’s stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $47.86, for a total transaction of $992,951.42. Following the completion of the sale, the chief executive officer now directly owns 27,555 shares in the company, valued at approximately $1,318,782.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Matt Scribner sold 4,102 shares of the company’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $43.82, for a total value of $179,749.64. Following the sale, the executive vice president now owns 6,435 shares of the company’s stock, valued at $281,981.70. The disclosure for this sale can be found here.
A number of large investors have added to or reduced their stakes in INGN. California State Teachers Retirement System boosted its stake in Inogen by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,132 shares of the medical technology company’s stock worth $1,168,000 after buying an additional 400 shares during the period. Sei Investments Co. boosted its stake in Inogen by 18.1% in the fourth quarter. Sei Investments Co. now owns 31,851 shares of the medical technology company’s stock worth $1,277,000 after buying an additional 4,880 shares during the period. First Trust Advisors LP acquired a new stake in Inogen during the fourth quarter worth approximately $2,419,000. Cornerstone Capital Management Holdings LLC. boosted its stake in Inogen by 29.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 93,441 shares of the medical technology company’s stock worth $3,746,000 after buying an additional 21,141 shares during the period. Finally, Thornburg Investment Management Inc. boosted its stake in Inogen by 7.7% in the fourth quarter. Thornburg Investment Management Inc. now owns 230,995 shares of the medical technology company’s stock worth $9,261,000 after buying an additional 16,500 shares during the period.
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company offers Inogen One systems, such as Inogen One G3 and G2 that concentrate the air around the patients to offer a single source of supplemental oxygen.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.